Oncology Institute (TOI) CFO reports RSU tax-related share sale

Rhea-AI Filing Summary

Oncology Institute, Inc. Chief Financial Officer Robert Ross Carter reported an "other" type transaction involving 1,314 shares of common stock at $3.59 per share on March 17, 2026. According to the disclosure, the issuer executed the sale to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on that date, making this a tax-related, non-discretionary event rather than an open-market trade. Following the transaction, Carter directly held 233,811 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carter Robert Ross

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Other	Common Stock	1,314	$3.59	$5K

Holdings After Transaction: Common Stock — 233,811 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Robert Ross

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD #800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		J(1)		1,314	D	$3.59	233,811	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Robert Carter	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Oncology Institute (TOI) report for its CFO?

Oncology Institute’s Chief Financial Officer Robert Ross Carter reported an "other" transaction involving 1,314 common shares. The issuer sold these shares to cover tax liabilities from an RSU vesting, and Carter’s direct holdings afterward totaled 233,811 shares.

Was the TOI CFO’s Form 4 transaction a normal buy or sell of shares?

The transaction was not a standard open-market buy or sell. It was coded as an "other" transaction, with the issuer selling 1,314 shares specifically to cover tax liabilities from a vested RSU award on March 17, 2026.

How many Oncology Institute (TOI) shares were involved in the CFO’s tax-related transaction?

The tax-related transaction involved 1,314 shares of Oncology Institute common stock at $3.59 per share. These shares were sold by the issuer to satisfy tax obligations triggered when a restricted stock unit award vested on March 17, 2026.

How many Oncology Institute (TOI) shares does the CFO hold after this Form 4 event?

After the reported transaction, Chief Financial Officer Robert Ross Carter directly held 233,811 shares of Oncology Institute common stock. This figure reflects his position following the 1,314-share sale executed by the issuer to cover RSU-related tax liabilities.

What does the footnote in the TOI CFO’s Form 4 filing explain?

The footnote explains that Oncology Institute executed the sale to cover tax liabilities from the vesting of an RSU award on March 17, 2026. It clarifies the event was tax-driven, not a discretionary open-market trade by the CFO.